yjoc_a_1728861_sm0984.docx (46.88 kB)

Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer

Download (46.88 kB)
journal contribution
posted on 18.02.2020, 09:58 by Motofumi Maruta, Takanori Miyoshi, Naomi Matsuo, Takuya Yamashina, Kenji Irie, Minako Tsuruta, Hiroko Tsukada, Moeko Tsuruyama, Masahisa Nagano, Yoichi Hiraki

We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3 h prior to the start of a 4 h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for the second cycle. We performed an analysis of the PKs of L-OHP during these two cycles. Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively. A dose reduction of L-OHP by 30%−50% may be advisable for the initial administration, given the need for careful administration of chemotherapy in HD patients, with particular attention to the development of hematological toxicities and neuropathy.

History

Licence

Exports